Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study

With the expanding use of sodium-glucose cotransporter 2 inhibitors, pharmacovigilance data can help characterize rare but serious adverse drug reactions such as diabetic ketoacidosis. To describe the clinical spectrum and age-related differences in sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis and identify distinct clinical presentation patterns using the French Pharmacovigilance Database. We conducted a retrospective nationwide case-series study including all expert-adjudicated reports of sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis recorded in the French Pharmacovigilance Database up to December 31, 2025. Clinical characteristics were compared between patients aged < 65 and ≥ 65 years. Unsupervised clustering was used to identify clinical presentation patterns. Among 299 reports screened, 242 expert-adjudicated cases of ketoacidosis were included (median age 67 years [interquartile range 57–76]; 43% women), of which 88 (36%) fulfilled all three 2024 ADA/EASD diagnostic domains. Euglycemic DKA occurred in 64/165 patients with available blood glucose data (39%), moderate-to-severe metabolic acidosis in 107/177 patients with available pH data (60%), and 100/240 patients with available ICU data (42%) were admitted to an ICU. Three clinical presentation patterns were identified: (1) a fasting-related phenotype characterized by gastrointestinal symptoms and fasting; (2) a perioperative phenotype associated with recent surgery; and (3) an infection-related phenotype characterized by infection, neurological symptoms, and falls, predominantly affecting older patients. Neither moderate-to-severe acidosis nor ICU admission differed significantly between age groups. Sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis shows heterogeneous presentations in routine practice. Older adults more often presented with atypical manifestations, whereas younger patients more often exhibited gastrointestinal symptoms. In older adults receiving sodium-glucose cotransporter 2 inhibitors, ketoacidosis should be considered when infection, neurological symptoms, or falls occur, even in the absence of gastrointestinal symptoms.

Authors

Institutions

Publication Details

Journal
Aging Clinical and Experimental Research
Published
2026-11-17
DOI
https://doi.org/10.1007/s40520-026-03566-2
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study

Marie‐Laure Laroche, Pierre‐Jean Saulnier, Marion Allouchery, Nassir Mirfendereski et al.
3 links
Aging Clinical and Experimental Research
Diabetes Treatment and Management
article

Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study

Marie‐Laure Laroche, Pierre‐Jean Saulnier, Marion Allouchery, Nassir Mirfendereski, Bérenger Largeau, Sophie Fédrizzi, Marlène Damin‐Pernik, Jean‐Luc Faillie, Brahim Azzouz, Héléna Mosbah, Nathanaël Bassas Letissier, Marc Paccalin
article en

Abstract

With the expanding use of sodium-glucose cotransporter 2 inhibitors, pharmacovigilance data can help characterize rare but serious adverse drug reactions such as diabetic ketoacidosis. To describe the clinical spectrum and age-related differences in sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis and identify distinct clinical presentation patterns using the French Pharmacovigilance Database. We conducted a retrospective nationwide case-series study including all expert-adjudicated reports of sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis recorded in the French Pharmacovigilance Database up to December 31, 2025. Clinical characteristics were compared between patients aged < 65 and ≥ 65 years. Unsupervised clustering was used to identify clinical presentation patterns. Among 299 reports screened, 242 expert-adjudicated cases of ketoacidosis were included (median age 67 years [interquartile range 57–76]; 43% women), of which 88 (36%) fulfilled all three 2024 ADA/EASD diagnostic domains. Euglycemic DKA occurred in 64/165 patients with available blood glucose data (39%), moderate-to-severe metabolic acidosis in 107/177 patients with available pH data (60%), and 100/240 patients with available ICU data (42%) were admitted to an ICU. Three clinical presentation patterns were identified: (1) a fasting-related phenotype characterized by gastrointestinal symptoms and fasting; (2) a perioperative phenotype associated with recent surgery; and (3) an infection-related phenotype characterized by infection, neurological symptoms, and falls, predominantly affecting older patients. Neither moderate-to-severe acidosis nor ICU admission differed significantly between age groups. Sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis shows heterogeneous presentations in routine practice. Older adults more often presented with atypical manifestations, whereas younger patients more often exhibited gastrointestinal symptoms. In older adults receiving sodium-glucose cotransporter 2 inhibitors, ketoacidosis should be considered when infection, neurological symptoms, or falls occur, even in the absence of gastrointestinal symptoms.

Aging Clinical and Experimental Research
Université de Tours (FR), Inserm (FR), Université de Montpellier (FR), Université de Poitiers (FR), Centre Hospitalier Universitaire de Montpellier (FR), Centre Hospitalier Universitaire de Tours (FR), Centre Hospitalier Universitaire de Reims (FR), Laboratoire de Physique Corpusculaire de Caen (FR), Centre Hospitalier Universitaire de Poitiers (FR), Centre Hospitalier Universitaire de Caen Normandie (FR), Centre Hospitalier Universitaire de Limoges (FR), Services déconcentrés d'appui à la recherche Val de Loire (FR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Membrane Signalling and Inflammation in reperfusion Injuries (FR), Université de Limoges (FR), Université de Reims Champagne-Ardenne (FR), Université de Caen Normandie (FR)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon